Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease

References

• Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62:1–8.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(suppl 1):S19–S32.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med. 2008;359:2468–2476.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Emre M, Jenner P, et al. Levodopa in the treatment of Parkinson’s disease. Eur J Neurol. 2009;16:982–989.
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimization in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet. 2006;45:109–136.
   PubMed Web of Science ®Google Scholar
• Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson’s disease. Parkinsonism Relat Disord. 2009 Dec;15(Suppl 3):S68–71.
   PubMedGoogle Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol. 2005;252(Suppl. 4):IV 37–42.
   Google Scholar
• Stocchi F, Antonini A, Barone P, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord. 2014;20(2):204–211.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;11:11–16.
   Web of Science ®Google Scholar
• Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs. 1998;55(Suppl 1):1–9.
   PubMed Web of Science ®Google Scholar
• Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson’s disease. Neurology. 1989;39(suppl 2):7–10.
   PubMedGoogle Scholar
• Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80:452–458.
   PubMed Web of Science ®Google Scholar
• Nyholm H, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2008;4:193–203.
   PubMed Web of Science ®Google Scholar
• Crevoisier C, Zerr P, Calvi-Gries F, et al. Effects of food on thepharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm. 2003;55:71–76.
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006;29:61–67.
   PubMed Web of Science ®Google Scholar
• Adler CH. Relevance of motor complications in Parkinson’s disease. Neurology. 2002;58(4 Suppl 1):S51–S56.
   PubMed Web of Science ®Google Scholar
• Olanow CW. Stocchi F Levodopa: A new look at an old friend. Mov Disord. 2017 Nov 27. DOI:10.1002/mds.27216
   Web of Science ®Google Scholar
• Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord. 2008;23(Suppl 3):S599–612.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Ondo WG, Van Lunen B, et al. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32:89–93.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38:89–103.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31(9):1366–1372.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Emerich D, Snodgrass-Belt P, et al. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson’s disease. J Pharmacol Exp Ther. 2004;310:828–835.
   PubMed Web of Science ®Google Scholar
• Freed MI, Batycky R, Merica E. Safety, tolerability, and pharmacokinetics following inhaled administration of CVT-301, a levodopa powder aerosol, in healthy adult subjects [abstract]. Mov Disord. 2013;28(Suppl 1):430.
   Google Scholar
• DeLong M, Wright J, Dawson M, et al. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med. 2005;18:452–459.
   PubMedGoogle Scholar
• Rave K, de la Pena A, Tibaldi FS, et al. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care. 2007;30:1777–1817.
   PubMed Web of Science ®Google Scholar
• Healy AM, Amaro MI, Paluch KJ, et al. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014;8:32–35.
   Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016 Oct 12;8:360ra136.
   PubMed Web of Science ®Google Scholar
• Grosset N, Malek F, Morgan D, et al. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol. 2013;20:1445–1450.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016 Sep;31(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• Grosset D, Dhall R, Gurevich T et al. Long-Term efficacy of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study. IAPRD Congress (XXII World Congress on Parkinson’s Disease and Related Disorders); 2017 Nov 12–15; Vietnam. Abstracts Pag. 45 OP-4-07.
   Google Scholar
• LeWitt PA, Pahwa R, Sedkov A, et al. Pulmonary safety and tolerability of inhaled levodopa (CVT-301) administered to patients with Parkinson’s disease. J Aerosol Med Pulm Drug Deliv. 2017 Nov 21. Epub ahead of print. DOI:10.1089/jamp.2016.1354
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179–187.
   PubMed Web of Science ®Google Scholar
• Sabate M, Gonz_Alez I, Ruperez F, et al. Obstructive and restrictive pulmonary dysfunctions in Parkinson’s disease. J Neurol Sci. 1996;138:114–119.
   PubMedGoogle Scholar
• Grosset D, Dhall R, Gurevich T, et al. Long-Term pulmonary safety of inhaled levodopa in Parkinson’s disease subjects with motor fluctuations: interim results of a phase 3 study. IAPRD Congress (XXII World Congress on Parkinson’s Disease and Related Disorders); 2017 Nov 12–15; Ho Chi Minh city,Vietnam. Abstracts P-161 (pag 195).
   Google Scholar
• Luinstra M, Grasmeijer F, Hagedoorn P, et al. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. Eur J Pharm Biopharm. 2015;97:22–29.
   PubMed Web of Science ®Google Scholar